UCL's gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.
Freeline, a UK-based gene therapy spinout from University College London (UCL) formed by commercialisation firm Syncona, has filed for a $100m initial public offering in the United States that will give pharmaceutical firm Novo the chance to exit.
Freeline is developing adeno-associated virus (AAV) gene therapies, and the AAVS3 virus that forms the basis of its drug candidates was developed at University College London by a team led by co-founder Amit Nathwani.
The IPO proceeds will be used to take a product candidate known as FLT180a through the completion of an ongoing phase 1/2 clinical trial for haemophilia B and a phase 1/2 trial for a second candidate, FLT190, in a rare genetic disease known as Fabry disease.
The offering will come after $275m in funding, including a $120m series C round co-led by firm Novo, Eventide Asset Management and Wellington Management last month.
…
